CTMX

CytomX Therapeutics, Inc. CTMX

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode CTMX ASMB SPRO TIL MGNX SYRE KALA
6M 530.99 % 191.96 % 275.00 % 27.94 % 31.01 % 56.63 % -57.57 %
YTD 216.98 % 54.58 % 108.33 % -11.05 % -48.79 % -19.75 % -81.45 %
1Y 208.26 % 55.85 % 82.93 % -55.87 % -60.51 % -37.57 % -72.34 %
3Y 136.62 % 32.29 % 13.07 % -79.10 % -50.44 % 63.87 % -89.04 %
5Y -51.30 % -85.96 % -83.85 % -96.36 % -93.44 % -90.33 % -99.67 %
10Y -72.75 % -76.82 % -80.43 % -96.36 % -93.28 % -92.16 % -99.85 %
From the beginning -73.95 % -92.99 % -80.43 % -96.36 % -93.24 % -92.16 % -99.85 %

Dividend

Spero Therapeutics, Inc.